دورية أكاديمية
أعرض في EDS

A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers.

التفاصيل البيبلوغرافية
العنوان: A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers.
المؤلفون: Chia BSH; Division of Radiation Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore., Ho SZ; Department of Radiation Oncology, 585 North Bridge Rd, Level 10 Raffles Specialist Centre, Singapore 188770, Singapore., Tan HQ; Division of Radiation Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore., Chua MLK; Division of Radiation Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore., Tuan JKL; Division of Radiation Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.
المصدر: Cancers [Cancers (Basel)] 2023 Jan 05; Vol. 15 (2). Date of Electronic Publication: 2023 Jan 05.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Regional hyperthermia therapy (RHT) is a treatment that applies moderate heat to tumours in an attempt to potentiate the effects of oncological treatments and improve responses. Although it has been used for many years, the mechanisms of action are not fully understood. Heterogenous practices, poor quality assurance, conflicting clinical evidence and lack of familiarity have hindered its use. Despite this, several centres recognise its potential and have adopted it in their standard treatment protocols. In recent times, significant technical improvements have been made and there is an increasing pool of evidence that could revolutionise its use. Our narrative review aims to summarise the recently published prospective trial evidence and present the clinical effects of RHT when added to standard cancer treatments. In total, 31 studies with higher-quality evidence across various subsites are discussed herein. Although not all of these studies are level 1 evidence, benefits of moderate RHT in improving local tumour control, survival outcomes and quality of life scores were observed across the different cancer subsites with minimal increase in toxicities. This paper may serve as a reference when considering this technique for specific indications.
References: J Cancer Res Ther. 2010 Oct-Dec;6(4):492-6. (PMID: 21358087)
Int J Hyperthermia. 2006 Jun;22(4):301-18. (PMID: 16754351)
Strahlenther Onkol. 2012 Sep;188 Suppl 2:198-211. (PMID: 22926657)
Int J Hyperthermia. 1990 Mar-Apr;6(2):279-85. (PMID: 2182746)
Int J Clin Oncol. 2007 Jun;12(3):192-8. (PMID: 17566842)
Int J Hyperthermia. 1990 Sep-Oct;6(5):881-90. (PMID: 2250114)
Int J Radiat Oncol Biol Phys. 2020 Jul 1;107(3):499-511. (PMID: 32179132)
Int J Hyperthermia. 2021;38(1):144-151. (PMID: 33557636)
Lancet Oncol. 2010 Jun;11(6):561-70. (PMID: 20434400)
Front Oncol. 2020 Jun 12;10:819. (PMID: 32596144)
Strahlenther Onkol. 2011 Oct;187(10):619-25. (PMID: 21932025)
Lancet. 2000 Apr 1;355(9210):1119-25. (PMID: 10791373)
Evid Based Complement Alternat Med. 2013;2013:672873. (PMID: 23662149)
Asia Oceania J Obstet Gynaecol. 1991 Mar;17(1):5-12. (PMID: 2064591)
Int J Radiat Oncol Biol Phys. 1996 Jul 1;35(4):731-44. (PMID: 8690639)
Int J Hyperthermia. 2016;32(1):31-40. (PMID: 26928474)
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818806003. (PMID: 30336769)
Antioxidants (Basel). 2022 Mar 24;11(4):. (PMID: 35453310)
Int J Hyperthermia. 1990 Jul-Aug;6(4):719-40. (PMID: 2203848)
Int J Hyperthermia. 2018 Nov;34(7):969-979. (PMID: 29168401)
Oncol Lett. 2017 Jul;14(1):73-78. (PMID: 28693137)
Strahlenther Onkol. 2017 May;193(5):351-366. (PMID: 28251250)
Biomed Res Int. 2020 Nov 13;2020:8814878. (PMID: 33274226)
Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):145-53. (PMID: 15629605)
Front Oncol. 2020 Sep 04;10:1690. (PMID: 33014841)
Int J Radiat Oncol Biol Phys. 1984 Jun;10(6):787-800. (PMID: 6547421)
Strahlenther Onkol. 2011 Oct;187(10):605-10. (PMID: 21932026)
J Clin Pharm Ther. 2017 Apr;42(2):155-164. (PMID: 28120520)
Int J Hyperthermia. 1993 Jan-Feb;9(1):19-24. (PMID: 8433024)
Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):411-437. (PMID: 30391522)
Am J Clin Oncol. 1991 Apr;14(2):133-41. (PMID: 1903023)
Int J Hyperthermia. 2011;27(1):27-32. (PMID: 20858088)
Eur J Cancer. 2021 Oct 16;158:123-132. (PMID: 34666214)
Int J Hyperthermia. 1990 May-Jun;6(3):479-86. (PMID: 2198311)
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820963599. (PMID: 33025843)
J Surg Oncol. 1995 Sep;60(1):55-8. (PMID: 7545257)
J Adv Res. 2020 Mar 17;24:175-182. (PMID: 32368355)
Mol Clin Oncol. 2017 May;6(5):723-732. (PMID: 28529748)
Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006377. (PMID: 20238344)
Australas Radiol. 1996 Aug;40(3):298-305. (PMID: 8826739)
Front Oncol. 2017 Jun 30;7:132. (PMID: 28713771)
Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1176-82. (PMID: 17881144)
Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):163-9. (PMID: 8270437)
Int J Hyperthermia. 2001 Mar-Apr;17(2):97-105. (PMID: 11252361)
Int J Hyperthermia. 2016 Nov;32(7):809-21. (PMID: 27411568)
Clin Exp Med. 2022 Nov;22(4):519-565. (PMID: 35767077)
J BUON. 2016 Mar-Apr;21(2):407-11. (PMID: 27273951)
Strahlenther Onkol. 2019 Jul;195(7):607-614. (PMID: 30390114)
Int J Hyperthermia. 2018 Jun;34(4):461-468. (PMID: 28679349)
Radiother Oncol. 2019 Nov;140:150-158. (PMID: 31302345)
J Clin Oncol. 2005 May 1;23(13):3079-85. (PMID: 15860867)
Int J Radiat Oncol Biol Phys. 1996 Mar 15;34(5):1097-104. (PMID: 8600093)
Asian Pac J Cancer Prev. 2013;14(12):7395-400. (PMID: 24460309)
Int J Hyperthermia. 1985 Jul-Sep;1(3):207-17. (PMID: 3836268)
Ann Surg. 2014 Nov;260(5):749-54; discussion 754-6. (PMID: 25379845)
PLoS One. 2019 Jun 19;14(6):e0217894. (PMID: 31216321)
Int J Radiat Biol. 2014 Oct;90(10):853-8. (PMID: 24758521)
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD006269. (PMID: 19588384)
Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1073-87. (PMID: 26899950)
Int J Hyperthermia. 2019;36(1):1024-1039. (PMID: 31621437)
Radiother Oncol. 2016 Sep;120(3):378-382. (PMID: 26897513)
JAMA Oncol. 2018 Apr 01;4(4):483-492. (PMID: 29450452)
Front Oncol. 2020 Mar 24;10:376. (PMID: 32266151)
Int J Hyperthermia. 2021;38(1):939-947. (PMID: 34134574)
Int J Hyperthermia. 2016 Nov;32(7):801-8. (PMID: 27418208)
Cancers (Basel). 2022 Jan 27;14(3):. (PMID: 35158924)
Int J Hyperthermia. 1992 May-Jun;8(3):289-95. (PMID: 1607733)
Int J Hyperthermia. 2020;37(1):263-272. (PMID: 32180481)
Cancer Treat Rev. 2015 Nov;41(9):742-53. (PMID: 26051911)
Adv Drug Deliv Rev. 2020;163-164:3-18. (PMID: 32229271)
Eur J Surg Oncol. 1995 Aug;21(4):374-8. (PMID: 7664901)
Int J Hyperthermia. 2021;38(1):1333-1340. (PMID: 34477028)
Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):78-87. (PMID: 29066122)
Tumori. 2014 Jan-Feb;100(1):49-54. (PMID: 24675491)
فهرسة مساهمة: Keywords: cancer management; cancer treatment; complementary therapy; electro hyperthermia; hyperthermia; locoregional moderate hyperthermia; review
تواريخ الأحداث: Date Created: 20230121 Latest Revision: 20230123
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9856725
DOI: 10.3390/cancers15020346
PMID: 36672300
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers15020346